Distinct immunohistochemical phenotype of nonmelanoma skin cancers between renal transplant and immunocompetent populations

Transplantation

Volumn 90, Issue 9, 2010, Pages 986-992

  Gutiérrez Dalmau, Alex ^a,b   Revuelta, Ignacio ^a   Ferrer, Berta ^a   Mascaró Jr , José M ^a   Oppenheimer, Federico ^a   Albanell, Joan ^c   Campistol, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

Kidney transplant recipients; Nonmelanoma skin cancer; P53; TGF

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID; PREDNISONE; PROTEIN P53; S6 KINASE; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; KIDNEY GRAFT; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

AGED; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHENOTYPE; SKIN NEOPLASMS;

EID: 78650286567     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181f6a0a1     Document Type: Article

References (35)

1. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: A systematic review. Drugs 2007; 67: 1167.
2. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001; 16: 1545.
3. Chapman JR, Webster AC. Cancer after renal transplantation: The next challenge. Am J Transplant 2004; 4: 841.
4. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Cecka JM, Terasaki PI, eds. Clinical transplants. Los Angeles, CA, UCLA Tissue Typing Laboratory 1998, pp 147.
5. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905.
6. Ulrich C, Kanitakis J, Stockfleth E, et al. Skin cancer in organ transplant recipients-Where do we stand today? Am J Transplant 2008; 8: 2192.
7. Nindl I, Rösl F. Molecular concepts of virus infections causing skin cancer in organ transplant recipients. Am J Transplant 2008; 8: 2199.
8. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell autonomous mechanism. Nature 1999; 397: 530.
9. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003; 76: 597.
10. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3: 371.
11. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9.
12. Kauffman HM, Cherikh WS, ChengY,etal. Maintenance immunosup-pression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883.
13. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581.
14. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multi-center studies. Clin Transplant 2004; 18: 446.
15. Moloney FJ, ComberH,O'LorcainP,etal.Apopulation-based study of skin cancer incidence and prevalence in renal transplant recipients.Br J Dermatol 2006; 154: 498.
16. Moosa MR, Gralla J. Skin cancer in renal allograft recipients-Experience in different ethnic groups residing in the same geographical region. Clin Transplant 2005; 19: 735.
17. Cecka JM. The OPTN/UNOS renal transplant registry. Clin Transpl 2004: 1.
18. Glover MT, Deeks JJ, Raftery MJ, et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997; 349: 398.
19. Buell JF, Hanaway MJ, Thomas M, et al. Skin cancer following transplantation: The Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005; 37: 962.
20. Fuente MJ, Sabat M, Roca J, et al. A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients. Br J Dermatol 2003; 149: 1221.
21. Ho WL, Murphy GM. Update on the pathogenesis of post-transplant skin cancer in renal transplant recipients. Br J Dermatol 2008; 158: 217.
22. Sarasin A, Giglia-Mari G. p53 gene mutations in human skin cancers. Exp Dermatol 2002; 11(suppl 1): 44.
23. Grossman D, Leffell DJ. The molecular basis of nonmelanoma skin cancer: New understanding. Arch Dermatol 1997; 133: 1263.
24. Hussein MR, Al-Badaiwy ZH, Guirguis MN. Analysis of p53 and bcl-2 protein expression in the non-tumorigenic, pretumorigenic, and tu-morigenic keratinocytic hyperproliferative lesions. J Cutan Pathol 2004; 31: 643.
25. Verdolini R, Amerio P, Goteri G, et al. Cutaneous carcinomas and preinvasive neoplastic lesions. Role of MMP-2 and MMP-9 metallo-proteinases in neoplastic invasion and their relationship with prolifer-ative activity and p53 expression. J Cutan Pathol 2001; 28: 120.
26. O'Connor DP, Kay EW, Leader M, et al. Altered p53 expression in benign and malignant skin lesions from renal transplant recipients and immunocompetent patients with skin cancer: Correlation with human papillomaviruses? Diagn Mol Pathol 2001; 10: 190.
27. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871.
28. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273: 1109.
29. Yarosh DB, Pena AV, Nay SL, et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125: 1020.
30. Nelson EW, Eichwald EJ, Shelby J. Increased ultraviolet radiation-induced skin cancers in cyclosporine-treated mice. Transplant Proc 1987; 19: 526.
31. Massagué J. TGFbeta in cancer. Cell 2008; 134: 215.
32. Sekulić A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000; 60: 3504.
33. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471.
34. Le XF, Hittelman WN, Liu J,et al. Paclitaxel induces inactivationofp70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 2003; 22: 484.
35. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004; 4: 335.